Read more
5:38 PM · 4 November 2021

Moderna stock plunges 20% after company cuts 2021 sales forecast

-
-
Open account Download free app

Moderna (MRNA.US) stock slumped 20% during today's session after the vaccine maker posted disappointing quarterly results and full-year earnings outlook. Moderna earned $7.70 per share on revenue of $5 billion, while analysts expected earnings of $9.05 on revenue of $6.2 billion. More concerning to investors is that the drugmaker cut its full-year sales forecast for its Covid-19 vaccine to between $15 billion and $18 billion from $20 billion. By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022. Moderna expects to deliver between 700 million and 800 million COVID-19 vaccine doses in 2021, down from the previous guidance of 800 million to 1 billion doses due to production and shipment issues. 

Moderna (MRNA.US) stock launched today's session with a massive bearish price gap and is currently testing major support at $280.00 which coincides with 61.8% Fibonacci retracement of the last upward wave and lower limit of the descending channel. Should a break lower occur, downward move may accelerate towards next support at $244.30, which is strengthened by 200 SMA (red line). On the other hand, if buyers manage to halt declines, another upward impulse towards resistance at $361.80 may be launched. Source: xStation5

12 February 2026, 7:03 PM

Daily summary: Silver plunges 9% 🚨Indices, crypto and precious metals under pressure

12 February 2026, 4:32 PM

Does the current sell-off signal the end of quantum companies?

12 February 2026, 3:58 PM

Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap 📈

12 February 2026, 3:40 PM

US Open: Cisco Systems slides 10% after earnings 📉 Mixed sentiments on Wall Street

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits